Repligen Co. (RGEN) Director Thomas F. Ryan, Jr. Sells 4,696 Shares
Repligen Co. (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 4,696 shares of the firm’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $36.16, for a total transaction of $169,807.36. Following the sale, the director now owns 9,700 shares of the company’s stock, valued at approximately $350,752. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Repligen Co. (RGEN) opened at $36.03 on Wednesday. Repligen Co. has a 12 month low of $29.56 and a 12 month high of $46.81. The company has a quick ratio of 8.08, a current ratio of 9.63 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1,624.54, a PE ratio of 50.75, a price-to-earnings-growth ratio of 2.51 and a beta of 0.94.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The business had revenue of $41.60 million during the quarter, compared to analysts’ expectations of $41.13 million. During the same quarter in the previous year, the company earned $0.08 EPS. The business’s revenue was up 62.5% on a year-over-year basis. equities analysts expect that Repligen Co. will post 0.7 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on the stock. BidaskClub upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 24th. Citigroup assumed coverage on shares of Repligen in a research note on Friday, December 8th. They issued a “buy” rating and a $45.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Repligen in a research note on Tuesday, December 5th. They issued an “overweight” rating and a $42.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $44.38.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/03/14/repligen-co-rgen-director-thomas-f-ryan-jr-sells-4696-shares.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.